News coverage about Abeona Therapeutics (NASDAQ:ABEO) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Abeona Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.3979088933645 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several equities analysts recently commented on the company. FBR & Co reissued a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, May 26th. Maxim Group set a $14.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Saturday, May 13th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, June 6th. HC Wainwright set a $20.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Finally, Zacks Investment Research raised Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Abeona Therapeutics currently has a consensus rating of “Buy” and an average price target of $17.86.
Abeona Therapeutics (NASDAQ:ABEO) opened at 8.25 on Tuesday. The company’s 50-day moving average price is $7.44 and its 200 day moving average price is $5.82. The firm’s market capitalization is $332.10 million. Abeona Therapeutics has a 52-week low of $3.43 and a 52-week high of $10.26.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, May 18th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million. Abeona Therapeutics had a negative return on equity of 26.99% and a negative net margin of 2,568.57%. Equities research analysts predict that Abeona Therapeutics will post ($0.57) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://stocknewstimes.com/2017/08/08/abeona-therapeutics-abeo-earning-somewhat-positive-press-coverage-analysis-shows.html.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
